|
|
|
|
| LEADER |
03619nam a2200625 4500 |
| 001 |
ocn915775232 |
| 003 |
OCoLC |
| 005 |
20170124070008.2 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
150803s2015 nju o 001 0 eng |
| 010 |
|
|
|a 2015030480
|
| 040 |
|
|
|a DLC
|b eng
|e rda
|c DLC
|d OCLCF
|d N$T
|d DG1
|d YDXCP
|d COO
|d IDEBK
|d CDX
|d EBLCP
|d RECBK
|d DEBBG
|d KSU
|d DEBSZ
|d GrThAP
|
| 020 |
|
|
|a 9781118914342 (epub)
|
| 020 |
|
|
|a 1118914341 (epub)
|
| 020 |
|
|
|a 9781118819449 (pdf)
|
| 020 |
|
|
|a 1118819446 (pdf)
|
| 020 |
|
|
|z 9781118679678 (cloth)
|
| 020 |
|
|
|a 9781118819586
|
| 020 |
|
|
|a 1118819586
|
| 020 |
|
|
|a 1118679679 (cloth)
|
| 020 |
|
|
|a 9781118679678 (cloth)
|
| 029 |
1 |
|
|a DEBBG
|b BV043399087
|
| 029 |
1 |
|
|a DEBSZ
|b 480371997
|
| 035 |
|
|
|a (OCoLC)915775232
|
| 042 |
|
|
|a pcc
|
| 050 |
0 |
0 |
|a HD9665.5
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 082 |
0 |
0 |
|a 615.1068/5
|2 23
|
| 049 |
|
|
|a MAIN
|
| 100 |
1 |
|
|a Alex, Alexander A.,
|e editor.
|
| 245 |
1 |
0 |
|a Attrition in the pharmaceutical industry :
|b reasons, implications, and pathways forward /
|c edited by Alexander A. Alex, C. John Harris, Dennis A. Smith.
|
| 264 |
|
1 |
|a Hoboken, New Jersey :
|b John Wiley & Sons,
|c 2015.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|2 rdacontent
|
| 337 |
|
|
|a computer
|2 rdamedia
|
| 338 |
|
|
|a online resource
|2 rdacarrier
|
| 500 |
|
|
|a Includes index.
|
| 505 |
0 |
|
|a Attrition in drug discovery and development / Scott Boyer, Clive Brealey and Andrew M. Davis -- Compound attrition at the pre-clinical phase / Cornelis E.C.A. Hop -- Attrition in phase I / Dennis A. Smith and Thomas A. Baillie -- Compound attrition in phase II/III / Alexander Alex, C. John Harris, Wilma W. Keighley and Dennis A. Smith -- Post-marketing attrition / Dennis A. Smith -- Influence of the regulatory environment on attrition / Robert T. Clay -- Experimental screening strategies to reduce attrition risk / Marie-Claire Peakman, Matthew Troutman, Rose Gonzales and Anne Schmidt -- Medicinal chemistry strategies to prevent compound attrition / J. Richard Morphy -- Influence of phenotypic and target-based screening strategies on compound attrition and project choice / Andrew Bell, Wolfgang Fecke and Christine Williams -- In silico approaches to address compound attrition / Peter Gedeck, Christian Kramer, Richard Lewis -- Current and future strategies for improving drug discovery efficiency / Peter Mbugua Njogu and Kelly Chibale -- Impact of investment strategies, organizational structure and corporate environment on attrition, and future investment strategies to reduce attrition / Geoff Lawton.
|
| 588 |
|
|
|a Description based on print version record and CIP data provided by publisher.
|
| 650 |
|
0 |
|a Pharmaceutical industry
|x Management.
|
| 650 |
|
0 |
|a Pharmaceutical industry
|x Capital productivity.
|
| 650 |
|
0 |
|a Industrial efficiency.
|
| 650 |
|
0 |
|a Drug development.
|
| 650 |
|
7 |
|a Drug development.
|2 fast
|0 (OCoLC)fst00898670
|
| 650 |
|
7 |
|a Industrial efficiency.
|2 fast
|0 (OCoLC)fst00970970
|
| 650 |
|
7 |
|a Pharmaceutical industry
|x Capital productivity.
|2 fast
|0 (OCoLC)fst01767658
|
| 650 |
|
7 |
|a Pharmaceutical industry
|x Management.
|2 fast
|0 (OCoLC)fst01060159
|
| 650 |
|
7 |
|a MEDICAL / Pharmacology
|2 bisacsh
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Harris, C. John,
|e editor.
|
| 700 |
1 |
|
|a Smith, Dennis A.,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|a Alex, Alexander A., editor.
|t Attrition in the pharmaceutical industry
|d Hoboken, New Jersey : John Wiley & Sons, 2015
|z 9781118679678
|w (DLC) 2015024772
|
| 856 |
4 |
0 |
|u https://doi.org/10.1002/9781118819586
|z Full Text via HEAL-Link
|
| 994 |
|
|
|a 92
|b DG1
|
